Shaily Engineering Plastics Q4 FY26: Healthcare scaling offsets a softer consumer cycle

Shaily Engineering Plastics closed FY26 with a sharp step up in profitability and a visible shift in revenue mix. On a consolidated basis, revenue rose to INR 990.7 crore in FY26, up 26 percent year-on-year. EBITDA increased 61 percent to INR 287.7 crore, and profit after tax grew 83 percent to INR 169.9 crore. Q4 FY26 continued the same trajectory with revenue at INR 236.8 crore, EBITDA at INR 69.3 crore, and PAT at INR 40.2 crore.

The key driver was healthcare. The company highlighted successful commercial launches of Shaily Harmony and Shaily Neo pen injectors for Semaglutide in India and other markets, and noted that a customer launched Shaily supplied Semaglutide pens in Canada. In parallel, consumer demand remained weak, especially in home furnishings across Europe and the US.

FY26 was defined by a mix shift toward healthcare

Segment performance explains the year. Healthcare revenue expanded to INR 392.8 crore in FY26 from INR 164.7 crore in FY25, a 139 percent increase. Its share of consolidated revenue rose to around 40 percent from 21 percent in FY25. In Q4, healthcare revenue doubled year-on-year to INR 112.8 crore.

Consumer revenue declined 9 percent in FY26 to INR 511.3 crore. In Q4, consumer revenue fell 31 percent to INR 102.1 crore, with management citing weaker market demand for home furnishings across Europe and the US, and also mentioning order cancellations from the Middle East in Q4 linked to the war. Industrial revenue grew 41 percent in FY26 to INR 86.6 crore, and rose 60 percent in Q4 to INR 21.9 crore, supported by new business in power tool and LED light components.

Capacity ramp-up is the near-term execution focus

Management commentary made it clear that the healthcare opportunity is now constrained more by ramp-up execution than by demand. The company said it is being asked for more Semaglutide pen volumes following the Canada launches, and is installing additional capacity.

On the call, management stated FY26 pen volumes were around 23.3 to 23.5 million devices, slightly below what had been discussed earlier, because capacities did not produce as projected. The company installed a new 25 million capacity line in March and said it is operating at around 45 percent overall equipment efficiency. Importantly, management acknowledged the learning curve and shared that rejection rates have reduced to about 8 percent on the line.

Management also indicated that another 25 million Semaglutide focused capacity is expected by July or August. For the two new lines, the stated target is to reach 65 to 67 parts per minute by the end of the year, which management said would translate into a combined effective output capacity of about 40 to 42 million pens for the year as ramp progresses.

This transparency also came with a candid risk statement: when asked about supply implications if ramp-up does not go as planned, management said that if the company cannot supply enough, then there is a risk.

New growth vectors: consumer electronics and semiconductor trays

FY26 also included early steps toward diversification beyond traditional home furnishings. The company stated it commenced commercial supplies to a consumer electronics customer during Q4 FY26, after multiple quarters of preparation and qualification. Management said supplies will happen both in India and through exports.

Shaily also announced that it signed an agreement with a Korean company for manufacture and supply of semiconductor trays. In Q&A, management said the trays will initially go to OSAT players and that supplies are expected to start in Q4 of the current financial year. The company positioned this as entry into the semiconductor supply chain, and said technical competence is critical because the trays are made of conductive plastic.

Capex will likely follow. Management said the company is evaluating setting up a plant down south for consumer electronics with an initial capex estimate of around INR 100 crore.

Capital flexibility and improving returns

The board approved an enabling resolution to raise up to INR 500 crore via permissible modes, including QIP and other instruments. Management emphasized this is intended to be an annual enabling resolution to preserve flexibility and is not a signal of an immediate fund raise.

From a returns standpoint, the company reported improved capital efficiency on a consolidated basis, with RoCE at 35.8 percent as of March 2026 versus 24.4 percent in March 2025, and RoE at 26.9 percent versus 18.5 percent. Debt to equity reduced to 0.3 from 0.4.

Takeaways

FY26 was a year where Shaily’s healthcare investments translated into scale and profits, while the consumer home furnishings cycle turned weaker. The next leg depends on how smoothly new pen injector lines ramp to rated speeds, and how quickly the company can convert early traction in consumer electronics and semiconductor trays into steady volumes. Management’s stance on margin sustainability was constructive, but the near-term execution risk remains tied to complex automation and capacity stabilization.